These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Absence of truncating BRIP1 mutations in chromosome 17q-linked hereditary prostate cancer families. Ray AM; Zuhlke KA; Johnson GR; Levin AM; Douglas JA; Lange EM; Cooney KA Br J Cancer; 2009 Dec; 101(12):2043-7. PubMed ID: 19935797 [TBL] [Abstract][Full Text] [Related]
4. A novel breast cancer-associated BRIP1 (FANCJ/BACH1) germ-line mutation impairs protein stability and function. De Nicolo A; Tancredi M; Lombardi G; Flemma CC; Barbuti S; Di Cristofano C; Sobhian B; Bevilacqua G; Drapkin R; Caligo MA Clin Cancer Res; 2008 Jul; 14(14):4672-80. PubMed ID: 18628483 [TBL] [Abstract][Full Text] [Related]
5. Mutational analysis of the breast cancer susceptibility gene BRIP1 /BACH1/FANCJ in high-risk non-BRCA1/BRCA2 breast cancer families. Guénard F; Labrie Y; Ouellette G; Joly Beauparlant C; Simard J; ; Durocher F J Hum Genet; 2008; 53(7):579. PubMed ID: 18414782 [TBL] [Abstract][Full Text] [Related]
6. BRIP1 loss-of-function mutations confer high risk for familial ovarian cancer, but not familial breast cancer. Weber-Lassalle N; Hauke J; Ramser J; Richters L; Groß E; Blümcke B; Gehrig A; Kahlert AK; Müller CR; Hackmann K; Honisch E; Weber-Lassalle K; Niederacher D; Borde J; Thiele H; Ernst C; Altmüller J; Neidhardt G; Nürnberg P; Klaschik K; Schroeder C; Platzer K; Volk AE; Wang-Gohrke S; Just W; Auber B; Kubisch C; Schmidt G; Horvath J; Wappenschmidt B; Engel C; Arnold N; Dworniczak B; Rhiem K; Meindl A; Schmutzler RK; Hahnen E Breast Cancer Res; 2018 Jan; 20(1):7. PubMed ID: 29368626 [TBL] [Abstract][Full Text] [Related]
7. Gene and pathway level analyses of germline DNA-repair gene variants and prostate cancer susceptibility using the iCOGS-genotyping array. Saunders EJ; Dadaev T; Leongamornlert DA; Al Olama AA; Benlloch S; Giles GG; Wiklund F; Gronberg H; Haiman CA; Schleutker J; Nordestgaard BG; Travis RC; Neal D; Pasayan N; Khaw KT; Stanford JL; Blot WJ; Thibodeau SN; Maier C; Kibel AS; Cybulski C; Cannon-Albright L; Brenner H; Park JY; Kaneva R; Batra J; Teixeira MR; Pandha H; Govindasami K; Muir K; ; ; ; Easton DF; Eeles RA; Kote-Jarai Z Br J Cancer; 2016 Apr; 114(8):945-52. PubMed ID: 26964030 [TBL] [Abstract][Full Text] [Related]
8. Mutation analysis of BRIP1/BACH1 in BRCA1/BRCA2 negative Chinese women with early onset breast cancer or affected relatives. Cao AY; Huang J; Hu Z; Li WF; Ma ZL; Tang LL; Zhang B; Su FX; Zhou J; Di GH; Shen KW; Wu J; Lu JS; Luo JM; Yuan WT; Shen ZZ; Huang W; Shao ZM Breast Cancer Res Treat; 2009 May; 115(1):51-5. PubMed ID: 18483852 [TBL] [Abstract][Full Text] [Related]
9. Truncating mutations in the Fanconi anemia J gene BRIP1 are low-penetrance breast cancer susceptibility alleles. Seal S; Thompson D; Renwick A; Elliott A; Kelly P; Barfoot R; Chagtai T; Jayatilake H; Ahmed M; Spanova K; North B; McGuffog L; Evans DG; Eccles D; ; Easton DF; Stratton MR; Rahman N Nat Genet; 2006 Nov; 38(11):1239-41. PubMed ID: 17033622 [TBL] [Abstract][Full Text] [Related]
10. Prevalence of the HOXB13 G84E germline mutation in British men and correlation with prostate cancer risk, tumour characteristics and clinical outcomes. Kote-Jarai Z; Mikropoulos C; Leongamornlert DA; Dadaev T; Tymrakiewicz M; Saunders EJ; Jones M; Jugurnauth-Little S; Govindasami K; Guy M; Hamdy FC; Donovan JL; Neal DE; Lane JA; Dearnaley D; Wilkinson RA; Sawyer EJ; Morgan A; Antoniou AC; Eeles RA; Ann Oncol; 2015 Apr; 26(4):756-761. PubMed ID: 25595936 [TBL] [Abstract][Full Text] [Related]
11. Tagging single nucleotide polymorphisms in the BRIP1 gene and susceptibility to breast and ovarian cancer. Song H; Ramus SJ; Kjaer SK; Hogdall E; Dicioccio RA; Whittemore AS; McGuire V; Hogdall C; Jacobs IJ; Easton DF; Ponder BA; Dunning AM; Gayther SA; Pharoah PD PLoS One; 2007 Mar; 2(3):e268. PubMed ID: 17342202 [TBL] [Abstract][Full Text] [Related]
12. No evidence that protein truncating variants in BRIP1 are associated with breast cancer risk: implications for gene panel testing. Easton DF; Lesueur F; Decker B; Michailidou K; Li J; Allen J; Luccarini C; Pooley KA; Shah M; Bolla MK; Wang Q; Dennis J; Ahmad J; Thompson ER; Damiola F; Pertesi M; Voegele C; Mebirouk N; Robinot N; Durand G; Forey N; Luben RN; Ahmed S; Aittomäki K; Anton-Culver H; Arndt V; ; Baynes C; Beckman MW; Benitez J; Van Den Berg D; Blot WJ; Bogdanova NV; Bojesen SE; Brenner H; Chang-Claude J; Chia KS; Choi JY; Conroy DM; Cox A; Cross SS; Czene K; Darabi H; Devilee P; Eriksson M; Fasching PA; Figueroa J; Flyger H; Fostira F; García-Closas M; Giles GG; Glendon G; González-Neira A; Guénel P; Haiman CA; Hall P; Hart SN; Hartman M; Hooning MJ; Hsiung CN; Ito H; Jakubowska A; James PA; John EM; Johnson N; Jones M; Kabisch M; Kang D; ; Kosma VM; Kristensen V; Lambrechts D; Li N; ; Lindblom A; Long J; Lophatananon A; Lubinski J; Mannermaa A; Manoukian S; Margolin S; Matsuo K; Meindl A; Mitchell G; Muir K; ; Nevelsteen I; van den Ouweland A; Peterlongo P; Phuah SY; Pylkäs K; Rowley SM; Sangrajrang S; Schmutzler RK; Shen CY; Shu XO; Southey MC; Surowy H; Swerdlow A; Teo SH; Tollenaar RA; Tomlinson I; Torres D; Truong T; Vachon C; Verhoef S; Wong-Brown M; Zheng W; Zheng Y; Nevanlinna H; Scott RJ; Andrulis IL; Wu AH; Hopper JL; Couch FJ; Winqvist R; Burwinkel B; Sawyer EJ; Schmidt MK; Rudolph A; Dörk T; Brauch H; Hamann U; Neuhausen SL; Milne RL; Fletcher O; Pharoah PD; Campbell IG; Dunning AM; Le Calvez-Kelm F; Goldgar DE; Tavtigian SV; Chenevix-Trench G J Med Genet; 2016 May; 53(5):298-309. PubMed ID: 26921362 [TBL] [Abstract][Full Text] [Related]
13. Mutation status of RAD51C, PALB2 and BRIP1 in 100 Japanese familial breast cancer cases without BRCA1 and BRCA2 mutations. Sato K; Koyasu M; Nomura S; Sato Y; Kita M; Ashihara Y; Adachi Y; Ohno S; Iwase T; Kitagawa D; Nakashima E; Yoshida R; Miki Y; Arai M Cancer Sci; 2017 Nov; 108(11):2287-2294. PubMed ID: 28796317 [TBL] [Abstract][Full Text] [Related]
14. Frequency of heterozygous germline pathogenic variants in genes for Fanconi anemia in patients with non-BRCA1/BRCA2 breast cancer: a meta-analysis. Alter BP; Best AF Breast Cancer Res Treat; 2020 Jul; 182(2):465-476. PubMed ID: 32488392 [TBL] [Abstract][Full Text] [Related]
15. Germline mutations in BRIP1 and PALB2 in Jewish high cancer risk families. Catucci I; Milgrom R; Kushnir A; Laitman Y; Paluch-Shimon S; Volorio S; Ficarazzi F; Bernard L; Radice P; Friedman E; Peterlongo P Fam Cancer; 2012 Sep; 11(3):483-91. PubMed ID: 22692731 [TBL] [Abstract][Full Text] [Related]
16. Germline genetic variants in men with prostate cancer and one or more additional cancers. Pilié PG; Johnson AM; Hanson KL; Dayno ME; Kapron AL; Stoffel EM; Cooney KA Cancer; 2017 Oct; 123(20):3925-3932. PubMed ID: 28657667 [TBL] [Abstract][Full Text] [Related]
17. Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50, and CDH1 mutations in high-risk Finnish BRCA1/2-founder mutation-negative breast and/or ovarian cancer individuals. Kuusisto KM; Bebel A; Vihinen M; Schleutker J; Sallinen SL Breast Cancer Res; 2011 Feb; 13(1):R20. PubMed ID: 21356067 [TBL] [Abstract][Full Text] [Related]
18. Mutation analysis of FANCD2, BRIP1/BACH1, LMO4 and SFN in familial breast cancer. Lewis AG; Flanagan J; Marsh A; Pupo GM; Mann G; Spurdle AB; Lindeman GJ; Visvader JE; Brown MA; Chenevix-Trench G; Breast Cancer Res; 2005; 7(6):R1005-16. PubMed ID: 16280053 [TBL] [Abstract][Full Text] [Related]
19. Genetic predisposition to prostate cancer. Benafif S; Eeles R Br Med Bull; 2016 Dec; 120(1):75-89. PubMed ID: 27941040 [TBL] [Abstract][Full Text] [Related]